Literature DB >> 3251401

Determinants of peak trabecular bone density in women: the role of androgens, estrogen, and exercise.

J R Buchanan1, C Myers, T Lloyd, P Leuenberger, L M Demers.   

Abstract

To elucidate determinants of peak trabecular bone density, we studied the role of androgens, estrogen, and aerobic exercise in 30 women from 18 to 22 years old. The women were divided into three groups: Sedentary, 11 normal women who did not exercise regularly; eumenorrheic, 10 athletes with normal menstrual function; and oligomenorrheic, 9 athletes with exercise-induced oligomenorrhea. All athletes participated in aerobic sports that did not involve selective resistance loading of the back. Serum free and albumin-bound testosterone (fab T), androstenedione (A), and estradiol (E2) were measured on four separate occasions at consecutive 7 day intervals and averaged. Trabecular density was measured by quantitative computed tomography of the lumbar spine. Peak trabecular bone density was related to fab T (r = 0.48, p = 0.007), A (r = 0.40, p = 0.03), and E2 (r = 0.40, p = 0.04). When taken in combination, androgens and estrogen each accounted independently for significant portions of the variance in bone density [fab T and E2 (R2 = 0.38, p = 0.002) and A and E2 (R2 = 0.27, p = 0.01)]. Bone density (mg/ml, mean +/- standard error of the mean, SEM) in the sedentary group (174 +/- 6) was not significantly different from that in the eumenorrheic (183 +/- 12, p = 0.47) or oligomenorrheic (161 +/- 11, p = 0.32) subjects. We conclude that androgens and estrogen function as independent and additive determinants of peak trabecular bone density in young women. The quantitative impact of aerobic exercise (without resistance loading) and exercise-induced menstrual dysfunction appears to be less important than that of the hormones.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3251401     DOI: 10.1002/jbmr.5650030613

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  15 in total

1.  Peak bone mineral area density and determinants among females aged 9 to 24 years in Mexico.

Authors:  Eduardo Lazcano-Ponce; Juan Tamayo; Aurelio Cruz-Valdez; Rodrigo Díaz; Bernardo Hernández; Ramón Del Cueto; Mauricio Hernández-Avila
Journal:  Osteoporos Int       Date:  2003-07-03       Impact factor: 4.507

2.  Estrogen status and heredity are major determinants of premenopausal bone mass.

Authors:  R Armamento-Villareal; D T Villareal; L V Avioli; R Civitelli
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

Review 3.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

Review 4.  Estrogen status and bone mass in the premenopausal period: is osteoporosis a developmental disease?

Authors:  R Civitelli; D T Villareal; R Armamento-Villareal
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

Review 5.  Clinical consequences of athletic amenorrhoea.

Authors:  N W Constantini
Journal:  Sports Med       Date:  1994-04       Impact factor: 11.136

6.  Influence of body parameters on female peak bone mass and bone loss.

Authors:  S Ortolani; C Trevisan; M L Bianchi; G Gandolini; R Cherubini; E E Polli
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 7.  DHEA and the skeleton (through the ages).

Authors:  C M Gordon; J Glowacki; M S LeBoff
Journal:  Endocrine       Date:  1999-08       Impact factor: 3.633

Review 8.  The role of exercise in preventing osteoporosis.

Authors:  S J Birge; G Dalsky
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

Review 9.  Optimizing peak bone mass: what are the therapeutic possibilities?

Authors:  S Adami
Journal:  Osteoporos Int       Date:  1994       Impact factor: 4.507

Review 10.  Can vigorous exercise play a role in osteoporosis prevention? A review.

Authors:  B Gutin; M J Kasper
Journal:  Osteoporos Int       Date:  1992-03       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.